Literature DB >> 6164789

Evaluation of CEA in patients with known residual disease after resection of colonic cancer.

J O Lawton, G R Giles, E H Cooper.   

Abstract

Serial carcinoembryonic antigen (CEA) levels were measured in 43 patients following incomplete excision of colorectal cancer. Twenty-seven patients received chemotherapy. In the majority the subsequent elevation of CEA could be related to clinical progression, but some patients receiving chemotherapy may have a suppressed rate of CEA rise and may have a more prolonged survival.The clinical application of serial CEA estimations remains of dubious value. However, one area which may be worthy of study is to determine whether suppression of the CEA slope by chemotherapy is attended by clinical control and an improved survival.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6164789      PMCID: PMC1440054          DOI: 10.1177/014107688007300106

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  11 in total

1.  Carcinoembryonic antigen in the diagnosis and management of colorectal carcinoma. Current status.

Authors:  A S Livingstone; L G Hampson; J Shuster; P Gold; E J Hinchey
Journal:  Arch Surg       Date:  1974-08

2.  The use of serial carcinoembryonic antigen determinations to predict recurrence of carcinoma of the colon and the time for a second-look operation.

Authors:  J P Minton; K K James; P E Hurtubise; L Rinker; S Joyce; E W Martin
Journal:  Surg Gynecol Obstet       Date:  1978-08

3.  Rising carcinoembryonic antigen titers in colorectal carcinoma: an indication for the second-look procedure.

Authors:  J R Nicholson; J C Aust
Journal:  Dis Colon Rectum       Date:  1978-04       Impact factor: 4.585

4.  Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (C.E.A.).

Authors:  J P Mach; P Jaeger; M M Bertholet; C H Ruegsegger; R M Loosli; J Pettavel
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

5.  Carcinoembryonic antigen test for recurrent colorectal carcinoma. Inadequacy for early detection.

Authors:  C G Moertel; A J Schutt; V L Go
Journal:  JAMA       Date:  1978-03-13       Impact factor: 56.272

6.  Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma.

Authors:  A Shani; M J O'Connell; C G Moertel; A J Schutt; A Silvers; V L Go
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

7.  Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinoma.

Authors:  M Ravry; C G Moertel; A J Schutt; V L Go
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

8.  CEA monitoring of palliative treatment for colorectal carcinoma.

Authors:  M A Herrera; T M Chu; E D Holyoke; A Mittelman
Journal:  Ann Surg       Date:  1977-01       Impact factor: 12.969

9.  Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma.

Authors:  D J Laurence; U Stevens; R Bettelheim; D Darcy; C Leese; C Turberville; P Alexander; E W Johns; A M Neville
Journal:  Br Med J       Date:  1972-09-09

10.  Specific carcinoembryonic antigens of the human digestive system.

Authors:  P Gold; S O Freedman
Journal:  J Exp Med       Date:  1965-09-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis.

Authors:  Zaiba Shafik Dawood; Laura Alaimo; Henrique A Lima; Zorays Moazzam; Chanza Shaikh; Ahmed Sayed Ahmed; Muhammad Musaab Munir; Yutaka Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2022-10-11       Impact factor: 4.339

Review 2.  The detection and evaluation of human tumor metastases.

Authors:  D J Laurence; A M Neville
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.